Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Theoretical Population Biology|September 24, 2018
Topological linkage disequilibrium calculated from coalescent genealogiesJohannes Wirtz, Martina Rauscher, Thomas Wiehe
Plos One|March 14, 2019
A common genomic code for chromatin architecture and recombination landscapeKamel Jabbari, Johannes Wirtz, Martina Rauscher, et al.
Life (Basel, Switzerland)|August 11, 2016
Ultra Large Gene Families: A Matter of Adaptation or Genomic Parasites?Philipp H Schiffer, Jan Gravemeyer, Martina Rauscher, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 31, 2022
Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine CandidateSanjay S Patel, Martina Rauscher, Maria Kudela, et al.
Vaccine|November 2, 2013
Interchangeability of Quinvaxem during primary vaccination schedules: results from a phase IV, single-blind, randomized, controlled, single-center, non-inferiority studyMaria Rosario Z Capeding, Corina Jica, Anna Macura-Biegun, et al.
Expert Review of Vaccines|March 18, 2025
Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccineMartina Rauscher, Zeb Youard, Alice Faccin, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 1, 2016
Comparison of the immunogenicity and safety of pentavalent vaccine Quinvaxem in a compact prefilled auto-disabled (cPAD) injection system versus single-dose vials in healthy infants: a phase 3, open-label, randomized, parallel-group, non-inferiority studyMaria Rosario Z Capeding, Edison Alberto, Amanda Versteilen, et al.
Vaccine|October 26, 2023
Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adultsVianney Tricou, Peter J Winkle, Leslie M Tharenos, et al.
Plos Neglected Tropical Diseases|March 8, 2023
Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled studyVianney Tricou, Brandon Essink, John E Ervin, et al.
Vaccine|January 21, 2023
A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic countryVianney Tricou, Susannah Eyre, Mahadev Ramjee, et al.
Pageof 3